• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The effect of molnupiravir on post-acute outcome of COVID-19 survivors.

作者信息

Hsu Wan-Hsuan, Shiau Bo-Wen, Tsai Ya-Wen, Wu Jheng-Yan, Liu Ting-Hui, Chuang Min-Hsiang, Lai Chih-Cheng

机构信息

Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan.

Divison of General Medicine, Department of Internal Medicine, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan.

出版信息

J Infect. 2023 Oct;87(4):339-343. doi: 10.1016/j.jinf.2023.03.016. Epub 2023 Mar 21.

DOI:10.1016/j.jinf.2023.03.016
PMID:36958635
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10029330/
Abstract
摘要

相似文献

1
The effect of molnupiravir on post-acute outcome of COVID-19 survivors.莫努匹拉韦对新冠病毒感染康复者急性后期结局的影响。
J Infect. 2023 Oct;87(4):339-343. doi: 10.1016/j.jinf.2023.03.016. Epub 2023 Mar 21.
2
Nirmatrelvir and Molnupiravir and Post-COVID-19 Condition in Older Patients.奈玛特韦、莫努匹拉韦与老年患者的新冠后状况
JAMA Intern Med. 2023 Dec 1;183(12):1404-1406. doi: 10.1001/jamainternmed.2023.5099.
3
Molnupiravir as the COVID-19 panacea: false beliefs in low- and middle-income countries.莫努匹拉韦作为治疗新冠肺炎的万灵药：低收入和中等收入国家的错误观念
Pathog Glob Health. 2023 Sep;117(6):525-526. doi: 10.1080/20477724.2023.2232593. Epub 2023 Jul 3.
4
Molnupiravir: A new candidate for COVID-19 treatment.莫努匹韦：COVID-19 治疗的新候选药物。
Pharmacol Res Perspect. 2022 Feb;10(1):e00909. doi: 10.1002/prp2.909.
5
Covid-19: What is the evidence for the antiviral molnupiravir?新冠病毒：抗新冠病毒药物莫努匹拉韦的证据有哪些？
BMJ. 2022 Apr 13;377:o926. doi: 10.1136/bmj.o926.
6
Molnupiravir for treatment of COVID-19.莫努匹韦用于治疗新型冠状病毒肺炎。
Med Lett Drugs Ther. 2022 Jan 24;64(1642):10-11.
7
Could Molnupiravir Be the First-Line Alternative Oral Antiviral Agent for COVID-19 Patients at High Risk?莫努匹韦能否成为高危COVID-19患者的一线替代口服抗病毒药物？
J Korean Med Sci. 2024 Feb 19;39(6):e74. doi: 10.3346/jkms.2024.39.e74.
8
Molnupiravir efficacy among immunocompromised patients with COVID-19: no proof of concept.莫努匹拉韦在免疫功能低下的新冠肺炎患者中的疗效：尚无概念验证。
Infection. 2023 Oct;51(5):1593-1595. doi: 10.1007/s15010-023-02027-6. Epub 2023 Apr 1.
9
Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study.阿兹夫定、莫努匹韦和奈玛特韦/利托那韦在轻中度 COVID-19 成年患者中的比较：一项回顾性队列研究。
Sci Rep. 2024 Feb 9;14(1):3318. doi: 10.1038/s41598-024-53862-y.
10
Additional analyses support superior efficacy of nirmatrelvir/ritonavir over molnupiravir for COVID-19.进一步分析表明，对于新冠病毒病，奈玛特韦/利托那韦比莫努匹韦疗效更佳。
J Med Virol. 2024 Feb;96(2):e29464. doi: 10.1002/jmv.29464.

引用本文的文献

1
Clinical effectiveness of oral antiviral treatment for non-hospitalized high-risk patients with COVID-19 during Omicron JN.1 subvariant wave: a US-based propensity-matched cohort study.奥密克戎 JN.1 亚变体流行期间口服抗病毒治疗对非住院 COVID-19 高危患者的临床疗效：一项基于美国的倾向匹配队列研究。
Pneumonia (Nathan). 2025 May 25;17(1):12. doi: 10.1186/s41479-025-00168-w.
2
Outcomes of non-hospitalized patients with COVID-19 versus seasonal influenza during the fall-winter 2022-2023 period.2022 - 2023年秋冬季节新冠病毒感染未住院患者与季节性流感患者的结局对比。
BMC Infect Dis. 2025 Mar 31;25(1):442. doi: 10.1186/s12879-025-10833-6.
3

本文引用的文献

1
Post-acute hospitalization and mortality of nirmatrelvir plus ritonavir for COVID-19 survivors.奈玛特韦片/利托那韦片对新冠病毒感染康复者急性住院治疗及死亡率的影响
J Infect. 2023 Apr;86(4):e107-e110. doi: 10.1016/j.jinf.2023.02.007. Epub 2023 Feb 10.
2
Molnupiravir for SARS-CoV-2 infection: Public health and policy implications.莫努匹拉韦用于治疗严重急性呼吸综合征冠状病毒2感染：对公共卫生和政策的影响
J Infect. 2023 Feb;86(2):121-122. doi: 10.1016/j.jinf.2022.10.040. Epub 2022 Dec 23.
3
The effect of nirmatrelvir plus ritonavir on the long-term risk of epilepsy and seizure following COVID-19: A retrospective cohort study including 91,528 patients.
Effectiveness of nirmatrelvir/ritonavir and molnupiravir on post-COVID-19 outcomes among outpatients: a target trial emulation investigation.
奈玛特韦/利托那韦和莫努匹拉韦对门诊新冠康复者预后的疗效：一项目标试验模拟研究
Emerg Microbes Infect. 2025 Dec;14(1):2469648. doi: 10.1080/22221751.2025.2469648. Epub 2025 Mar 4.
4
Effectiveness of molnupiravir for treating COVID-19 in patients with psychiatric disorders.莫努匹拉韦治疗精神疾病患者新冠病毒病的有效性
Front Pharmacol. 2024 Jul 4;15:1384264. doi: 10.3389/fphar.2024.1384264. eCollection 2024.
5
Comparison of post-acute sequelae following hospitalization for COVID-19 and influenza.比较因 COVID-19 和流感住院后的急性后期后遗症。
BMC Med. 2023 Dec 5;21(1):480. doi: 10.1186/s12916-023-03200-2.
6
The effect of bebtelovimab on clinical outcomes in patients with COVID-19: A meta-analysis.贝博泰洛维单抗对新冠病毒病患者临床结局的影响：一项荟萃分析。
J Infect. 2023 Jul;87(1):68-71. doi: 10.1016/j.jinf.2023.04.010. Epub 2023 Apr 19.
奈玛特韦片/利托那韦片对新型冠状病毒肺炎后癫痫和发作长期风险的影响：一项纳入91528例患者的回顾性队列研究。
J Infect. 2023 Mar;86(3):256-308. doi: 10.1016/j.jinf.2023.01.014. Epub 2023 Jan 14.
4
Long COVID: An inevitable sequela of SARS-CoV-2 infection.长新冠：SARS-CoV-2 感染的必然后遗症。
J Microbiol Immunol Infect. 2023 Feb;56(1):1-9. doi: 10.1016/j.jmii.2022.10.003. Epub 2022 Oct 15.
5
Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19 : A Randomized, Placebo-Controlled Trial.莫努匹韦对 COVID-19 生物标志物、呼吸干预和医疗服务的影响：一项随机、安慰剂对照试验。
Ann Intern Med. 2022 Aug;175(8):1126-1134. doi: 10.7326/M22-0729. Epub 2022 Jun 7.
6
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19.美国传染病学会关于2019冠状病毒病患者治疗与管理的指南
Clin Infect Dis. 2020 Apr 27. doi: 10.1093/cid/ciaa478.